NRIX
Nurix Therapeutics, Inc.
Latest close $24.69 as of Aug 4, 2026
Schedule 13G/13D reports beneficial ownership at an observation date. “Accumulation” or “reduction” is inferred
from changes in reported shares when available; it is not a list of individual trades or exact execution prices.
Form 13F rows are quarter-end holding context only and do not establish an exact entry date.
Free access includes current parsed ownership filings, reported share changes, and ownership-percentage changes.
Significance scoring, disclosure-speed analysis, confirmation/divergence signals, and signal alerts require Investor or Pro.
Compare plans.
Beneficial ownership filing history
Showing 3 of 4 parsed filing(s) · 1 older require more history access| Holder | Observed / filed | Reported change | Shares | Ownership | Observation | Filing | Latest |
|---|---|---|---|---|---|---|---|
| Vanguard Capital Management CIK0002100119 | Jun 30, 2026 observed Jul 31, 2026 filed · 31d Initial Schedule 13G | Initial Schedule 13G | 5.2M | 12.00% | $24.26 | $23.21 | $24.69 |
| Fidelity / FMR CIK0000315066 | Mar 31, 2026 observed May 6, 2026 filed · 36d Initial Schedule 13G | Initial Schedule 13G | 5.5K | 12.00% | $15.50 | $16.88 | $24.69 |
| BlackRock Legacy CIK0001364742 | May 31, 2024 observed Jun 7, 2024 filed · 7d Schedule 13G amendment | Reported accumulation | 6.0M +1.4M | 10.20% +0.60 pts | $15.68 | $24.69 |